Senolytics Target Senescent Cancer Cells for Death

D

Dr Joe Zundell PhD, cancer biologist, on Siim Land's podcast

General HealthMedical

Quotes From Source

“Senolytics target senescent pathways in cancers to induce...”

Story of claim

Senolytics, like BCL2 inhibitors, target senescent pathways to induce cell death in cancer cells. This approach aims to exploit the senescent state of cancer cells to eliminate them.

  • Goal: To induce cell death in cancer cells by targeting senescent pathways.
  • Proof: Senolytics, by targeting senescent pathways, can induce death in senescent cancer cells.
  • Nuances:
    • Use of BCL2 inhibitors
    • Targeting secretory factors like IL6
  • Impact on Life: Potentially improves treatment outcomes for patients with late-stage tumors by targeting resistant cancer cells.

Investments

  • Price:
  • Time:
  • Effort: High due to complexity in targeting diverse mechanisms

Risks

The complexity of diverse mechanisms in different cancer types may pose challenges.

Alternatives

  • Traditional chemotherapy
  • Radiation therapy

Get Started 🚀

  • Consult with an oncologist about senolytic therapies.
  • Research BCL2 inhibitors and their availability.
  • Consider combination with other cancer treatments.

Brogevity AI can make mistakes. Check important info.

Reference Video